Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Miguel Martín, Pablo Tolosa et al.|Breast Cancer Research and Treatment|2024Cited by 21
Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE projectRodrigo Sánchez-Bayona, Cristina Rodríguez‐Antona, Javier de Nicolás‐Hernández et al.|Clinical Cancer Research|2025Cited by 3
Abstract P3-01-04: A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancerRodrigo Sánchez-Bayona, Eva Ciruelos, Manuel Alva et al.|Cancer Research|2023Cited by 1